EBOS Group Limited (NZE:EBO)

New Zealand flag New Zealand · Delayed Price · Currency is NZD
19.84
+0.32 (1.64%)
Jun 2, 2026, 10:19 AM NZST
Market Cap4.04B -49.7%
Revenue (ttm)15.12B +3.5%
Net Income266.03M -6.7%
EPS1.31 -11.1%
Shares Out 206.93M
PE Ratio14.90
Forward PE13.27
Dividend1.30 (6.66%)
Ex-Dividend DateMar 5, 2026
Volume18,097
Open19.75
Previous Close19.52
Day's Range19.60 - 19.90
52-Week Range19.42 - 41.98
Beta0.20
AnalystsBuy
Price Target31.78 (+60.18%)
Earnings DateJun 1, 2026

About EBOS Group

EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and health communications, programs, and consultancy services. It also offers community based health care services and ... [Read more]

Sector Healthcare
Founded 1922
Employees 5,800
Stock Exchange New Zealand Stock Exchange
Ticker Symbol EBO
Full Company Profile

Financial Performance

In fiscal year 2025, EBOS Group's revenue was 12.27 billion, a decrease of -6.99% compared to the previous year's 13.19 billion. Earnings were 215.14 million, a decrease of -20.77%.

Financial numbers in AUD Financial Statements

News

EBOS Group Sees Capex Declining From FY27; Targets Mid-Single-Digit EBITDA Growth Over Medium-Term

(RTTNews) - EBOS Group Limited (EBO.AX), which markets and distributes healthcare, medical, pharmaceutical and animal care products in Australia, on Thursday outlined its strategy, growth plans and ca...

4 weeks ago - Nasdaq

EBOS Group Transcript: Investor Day 2026

EBITDA is set to triple over a decade as the portfolio shifts toward higher-growth, higher-return sectors, with 85% of earnings now from market-leading businesses. Major capital investments are concluding, enabling a focus on productivity, recurring earnings, and disciplined bolt-on M&A for future growth.

4 weeks ago - Transcripts

EBOS Group Slides: FY 2026

EBOS Group has posted slides in relation to its FY 2026 quarterly earnings report, which was published on April 29, 2026.

4 weeks ago - Filings

EBOS Group Issues Update To FY26 Earnings Outlook

(RTTNews) - EBOS Group (EBO.AX) issued an update on the impact of elevated fuel prices and broader energy cost pressures on the Group's fiscal 2026 earnings outlook. Based on current assumptions for t...

5 weeks ago - Nasdaq

EBOS Group Earnings Call Transcript: H1 2026

Revenue grew 13% to AUD 6.8 billion, with underlying EBITDA up 3.2% and strong segment performance in Healthcare and Animal Care. FY 2026 guidance is reaffirmed, with margin and cash flow improvements expected as the DC Renewal Program nears completion and productivity rises.

3 months ago - Transcripts

EBOS Group Quarterly report: H1 2026

EBOS Group has published its H1 2026 quarterly earnings report on February 24, 2026.

3 months ago - Filings

EBOS Group Slides: H1 2026

EBOS Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 24, 2026.

3 months ago - Filings

LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Ebos Group Ltd (EBO)

LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Ebos Group Ltd (EBO)

4 months ago - GuruFocus

EBOS Group Transcript: AGM 2025

The meeting reviewed strong revenue growth and strategic investments, but addressed challenges from the loss of a major contract, margin pressures, and a significant share price decline. Executive incentives were updated to better align with shareholder interests, and all board resolutions proceeded to vote.

7 months ago - Transcripts

EBOS Group Slides: FY 2025

EBOS Group has posted slides in relation to its FY 2025 quarterly earnings report, which was published on October 28, 2025.

7 months ago - Filings

EBOS Group Earnings Call Transcript: H2 2025

Solid organic growth and strategic acquisitions drove a 12% revenue and 7.5% EBITDA increase, despite the loss of a major contract. Competitive pressures and soft consumer demand persist, but guidance targets 7% EBITDA growth in FY 2026, with continued investment in infrastructure and cost management.

9 months ago - Transcripts

EBOS Group Slides: H2 2025

EBOS Group has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 26, 2025.

9 months ago - Filings

EBOS Group Annual report: H2 2025

EBOS Group has published its H2 2025 annual report on August 26, 2025.

9 months ago - Filings

UBS launches $NZ217m EBOS Group placement to fund acquisitions

New shares were priced at $NZ36.65 – a 5 per cent discount to the last close price.

1 year ago - The Australian Financial Review